Ebola vaccine shipment to Africa stymied

2014-09-04 05:51
A vaccine candidate to be tested in the upcoming Ebola drug trials. (NIAID/GSK)

A vaccine candidate to be tested in the upcoming Ebola drug trials. (NIAID/GSK)

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories

Winnipeg - Canada's experimental Ebola vaccine was stuck in the government lab that developed it as officials puzzled over how to safely transport it, three weeks after it was offered to Africa to fight the deadly epidemic.

Ottawa said on 12 August that it would donate between 800 and 1 000 doses of the vaccine to the World Health Organisation for use in Africa, where more than 1 900 people have died from the disease. The vaccines are being held at Canada's National Microbiology Laboratory in Winnipeg.

"We are now working with the WHO to address complex regulatory, logistical and ethical issues so that the vaccine can be safely and ethically deployed as rapidly as possible," said Health Canada spokesman Sean Upton said in a statement.

"For example, the logistics surrounding the safe delivery of the vaccine are complicated."

One challenge is keeping the vaccine cool enough to remain potent, Upton said.

Canadian officials were trying to define proper storage and transportation procedures, and they could not estimate when the vaccines would leave the lab.

Cases of Ebola have been reported in Liberia, Sierra Leone, Guinea, Nigeria, Senegal, and Democratic Republic of Congo. The cases in Congo, which include 31 deaths, are thought to be a separate outbreak and not related to the West African cases.

The United Nations said on Wednesday it would take $600m in supplies to control an outbreak of Ebola in West Africa as the death toll rose from the worst epidemic of the virus on record.

Spokespersons for WHO could not be immediately reached for comment. The organisation has backed the use of experimental Ebola drugs in West Africa on compassionate grounds.

Iowa-based NewLink Genetics Corporation holds the commercial license for the Canadian vaccine and said in August that it would be able to produce tens of thousands of vaccine doses within a month or two.

The US Department of Health and Human Services said on Tuesday a federal contract worth up to $42.3m would help accelerate testing of an experimental Ebola virus treatment being developed by privately held Mapp Biopharmaceutical.

Human safety trials are due to begin this week on a vaccine from GlaxoSmithKline Plc and later this year on one from NewLink Genetics Corp.

Read more on:    who  |  canada  |  ebola

Join the conversation!

24.com encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Inside News24


Book flights

Compare, Book, Fly

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.